1/7/2021 6:07:00 AM
Amarin Sees 2020 Total Net Revenue To Be About $610 Mln
12/13/2020 9:51:40 AM
Amarin Presents Encouraging Efficacy & Safety Results From Pilot Study Treating COVID-19 Infected Patients With VASCEPA
11/30/2020 8:26:11 PM
Amarin Files Patent Infringement Lawsuit Against Hikma
8/4/2020 6:37:32 AM
Amarin Plans To Undertake Its Own Focused Commercial Launch Of VASCEPA In Europe
6/15/2020 7:17:51 AM
Amarin Presents Data From The REDUCE-IT Study
6/1/2020 7:16:34 AM
Amarin To Increase Level And Breadth Of Promotion And Education Initiatives Regarding VASCEPA
1/7/2020 6:03:18 AM
Amarin Reiterates 2020 Net Total Revenue Guidance At $650 Mln-$700 Mln
1/2/2020 6:05:08 AM
Amarin Says VASCEPA Approved In Canada To Reduce Risk Of Cardiovascular Events